Meeting
2023 ASCO Annual Meeting
Imbalance in treatment discontinuation without progression between experimental and control arms among randomized trials in advanced breast cancer.
Authors
Faris Tamimi
Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada
Faris Tamimi , Abhenil Mittal , Consolacion Molto , Diego Malon Gimenez , Michelle B. Nadler , Eitan Amir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Other Breast Cancer Subtypes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1110)
DOI
10.1200/JCO.2023.41.16_suppl.1110
Abstract #
1110
Poster Bd #
331
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.
First Author: Tomás Pascual
Poster
2022 ASCO Annual Meeting
Ribociclib-induced acute kidney injury: Uncover the MONALEESA’s dark face.
First Author: Maissoune Hajir
Poster
2020 ASCO Virtual Scientific Program
Overall survival (OS) in patients (pts) with advanced breast cancer (ABC) with visceral metastases (mets), including those with liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials.
First Author: Denise A. Yardley
Poster
2024 ASCO Annual Meeting
Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.
First Author: Sherry Shen